 Niacinamide
"Niacinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
| Descriptor ID |
D009536
|
| MeSH Number(s) |
D03.066.515.530 D03.383.725.547.530
|
| Concept/Terms |
Niacinamide- Niacinamide
- Vitamin PP
- Vitamin B 3
- B 3, Vitamin
- Vitamin B3
- B3, Vitamin
- 3-Pyridinecarboxamide
- 3 Pyridinecarboxamide
- Nicotinamide
Papulex- Papulex
- Pharmagenix Brand of Niacinamide
- Niacinamide Pharmagenix Brand
Nicotinsäureamid Jenapharm- Nicotinsäureamid Jenapharm
- Jenapharm, Nicotinsäureamid
- Jenapharm Brand of Niacinamide
- Niacinamide Jenapharm Brand
Nicobion- Nicobion
- Merck Brand of Niacinamide
- Niacinamide Merck Brand
- Astra Brand of Niacinamide
- Niacinamide Astra Brand
|
Below are MeSH descriptors whose meaning is more general than "Niacinamide".
Below are MeSH descriptors whose meaning is more specific than "Niacinamide".
This graph shows the total number of publications written about "Niacinamide" by people in this website by year, and whether "Niacinamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Hu Y, Bobb D, He J, Hill DA, Dome JS. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Cancer Biol Ther. 2015; 16(6):949-57.
-
Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weigel B, Blaney SM. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Sep; 62(9):1562-6.
-
Hu Y, Bobb D, Lu Y, He J, Dome JS. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. Cancer Genet. 2014 Sep; 207(9):403-11.
-
Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer. 2013 Mar; 60(3):396-401.
-
Kim A, McCully C, Cruz R, Cole DE, Fox E, Balis FM, Widemann BC. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs. 2012 Apr; 30(2):524-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|